CRISPR Gene Editing for Neurodegeneration
Introduction
Mermaid diagram (expand to render)
Crispr Gene Editing For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.<style>
.infobox { float: right; width: 320px; margin-left: 20px; margin-bottom: 20px; background: #f8f9fa; border: 1px solid #ddd; border-radius: 4px; padding: 10px; font-size: 0.9em; } [@ran2013]
.infobox-header { background: #6f42c1; color: white; padding: 8px; margin: -10px -10px 10px -10px; border-radius: 4px 4px 0 0; font-weight: bold; text-align: center; } [@gaudelli2017]
.infobox-row { display: flex; justify-content: space-between; padding: 4px 0; border-bottom: 1px solid #eee; } [@zhang2023]
.infobox-row:last-child { border-bottom: none; } [@liu2022]
.infobox-label { font-weight: bold; color: #555; } [@nguyen2023]
</style> [@zeitler2024]
<div class="infobox"> [@liu2023]
<div class="infobox-header">CRISPR Gene Editing</div> [@pinsker2022]
<div class="infobox-row"><span class="infobox-label">Technology</span><span>CRISPR/Cas9, Base Editing, Prime Editing</span></div> [@gaj2022]
<div class="infobox-row"><span class="infobox-label">Delivery</span><span>AAV, LNP, Electroporation</span></div> [@krishnan2023]
<div class="infobox-row"><span class="infobox-label">Targets</span><span>APP, SNCA, HTT, SOD1, C9orf72</span></div> [@barmac2024]
<div class="infobox-row"><span class="infobox-label">Conditions</span><span>AD, PD, HD, ALS, FTD</span></div>
<div class="infobox-row"><span class="infobox-label">Development</span><span>Preclinical to Phase I</span></div>
</div>
Overview
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) gene editing technologies represent a revolutionary approach to treating neurodegenerative diseases by directly correcting disease-causing genetic mutations or reducing expression of toxic proteins. Unlike small molecule drugs or antibodies that must be administered repeatedly, gene editing offers the potential for durable, possibly curative treatments with a single intervention[@doudna2014].
The application of CRISPR technology to neurodegenerative diseases has advanced rapidly since the first demonstrations of CRISPR/Cas9-mediated gene editing in mammalian [neurons](/entities/neurons). Current approaches include:
- CRISPR/Cas9: Traditional CRISPR with double-strand breaks and non-homologous end joining (NHEJ) or homology-directed repair (HDR)
- Base Editing: Precise single-nucleotide changes without double-strand breaks
- Prime Editing: All 12 types of point mutations, small insertions, and deletions without double-strand breaks
- CRISPRi/a: Transcriptional interference or activation without DNA cleavage
Molecular Mechanisms
CRISPR/Cas9 System
The CRISPR/Cas9 system uses a guide RNA (gRNA) to direct the Cas9 nuclease to a specific genomic location, where it creates a double-strand break. The cell's DNA repair pathways then either:
Non-Homologous End Joining (NHEJ): Results in gene knockout through insertions/deletions (indels) that disrupt the reading frame
Homology-Directed Repair (HDR): Allows precise gene correction using a donor DNA template[@ran2013]For neurodegenerative diseases, both approaches have therapeutic applications:
- Gene Knockout: Disabling genes that cause toxic protein production (e.g., mutant [HTT](/proteins/htt-protein) in Huntington's disease, mutant SOD1 in ALS)
- Gene Correction: Repairing disease-causing mutations (e.g., APP Swedish mutation, [PSEN1](/entities/psen1) mutations in familial AD)
Base Editing
Base editors (BE) enable precise single-nucleotide conversions without creating double-strand breaks:
- Cytosine Base Editors (CBE): Convert C→T or C→G
- Adenine Base Editors (ABE): Convert A→G or A→T
- Prime Editors: Enable all types of point mutations plus insertions/deletions[@gaudelli2017]
Base editing offers improved safety compared to traditional CRISPR by reducing off-target effects and avoiding large genomic rearrangements.
CRISPR Delivery Strategies
Effective delivery to the central nervous system remains the key challenge for CRISPR therapeutics:
| Delivery Method | Advantages | Limitations | Clinical Status |
|-----------------|------------|-------------|------------------|
| AAV Vectors | Long-term expression, CNS tropism | Small cargo capacity (~4.7 kb), immune response | Preclinical |
| Lipid Nanoparticles (LNP) | Large cargo capacity, low immunogenicity | Transient expression | Phase I |
| Viral-like Particles (VLP) | No viral genome, transient expression | Manufacturing challenges | Preclinical |
| Electroporation | High efficiency (ex vivo) | Invasive (in vivo) | Ex vivo clinical |
| Ribonucleoprotein (RNP) | Immediate action, reduced off-target | Transient effect | Preclinical |
Disease-Specific Applications
Alzheimer's Disease
Gene Targets: APP, PSEN1, [PSEN2](/entities/psen2), [APOE](/proteins/apoe-protein)
Therapeutic Approaches:
APP Editing: Targeting the [amyloid precursor protein](/entities/app-protein) gene to reduce [Aβ](/proteins/amyloid-beta) production
- CRISPRi to reduce APP expression
- Base editing to correct familial AD mutations (Swedish, Arctic)
- CRISPR/Cas9 to disrupt APP processing sites[@zhang2023]
[APOE](/genes/apoe) Modulation: Editing APOE4 to APOE3 or APOE2
- Base editing to convert APOE4 (risk allele) to APOE3 (neutral)
- CRISPRa to increase APOE2 expression[@liu2022]
Preclinical Results:
- AAV-CRISPR targeting APP reduced plaque burden by 70% in APP/PS1 mice
- Base editing of APP Swedish mutation in neurons derived from patient iPSCs restored normal [Aβ](/proteins/amyloid-beta) secretion
- APOE4→APOE3 conversion improved neuronal survival in organoid models
Parkinson's Disease
Gene Targets: SNCA, LRRK2, GBA, PARK2 (Parkin), PINK1, DJ-1
Therapeutic Approaches:
[α-Synuclein](/proteins/alpha-synuclein) Reduction:
- CRISPRi to suppress SNCA expression
- CRISPR/Cas9 to disrupt regulatory elements
- Allele-specific editing of mutant SNCA (A53T)[@nguyen2023]
LRRK2 Modulation:
- Correction of G2019S mutation (most common LRRK2 variant)
- CRISPRi to reduce mutant expression[@zeitler2024]
GBA Enhancement:
- CRISPRa to increase glucocerebrosidase activity
- Correction of Gaucher disease mutations that increase PD risk[@liu2023]
Preclinical Results:
- AAV9-CRISPR/SNCA-gRNA reduced α-synuclein aggregation in mouse models
- LRRK2 G2019S correction restored normal kinase activity in patient-derived neurons
- GBA editing increased glucocerebrosidase activity by 40% in cell models
Huntington's Disease
Gene Target: [HTT](/genes/htt) (Huntingtin)
Therapeutic Approaches:
Mutant HTT Knockdown:
- CRISPRi to suppress mutant HTT expression
- Allele-specific editing using SNPs in linkage disequilibrium with expanded CAG[@pinsker2022]
CAG Repeat Contraction:
- Prime editing to reduce repeat length
- CRISPR/Cas9 with repeat-targeting gRNAs[@gaj2022]
Gene Correction:
- HDR-mediated correction of disease-causing mutation
- Base editing to disrupt cryptic splice sites[@krishnan2023]
Preclinical Results:
- CRISPRi reduced mutant HTT protein by 80% in HD mouse models
- Allele-specific editing in patient-derived neurons reduced mutant protein while preserving wild-type
- AAV-delivered CRISPR/Cas9 improved motor function in BACHD mice
Amyotrophic Lateral Sclerosis (ALS)
Gene Targets: SOD1, [C9orf72](/entities/c9orf72), FUS, [TARDBP](/proteins/tardbp-protein), UBQLN2
Therapeutic Approaches:
SOD1 Editing:
- CRISPRi for universal SOD1 reduction
- Allele-specific editing for A4V, G93A mutations[@barmac2024]
C9orf72 Reduction:
- CRISPR targeting the expanded repeat or promoter
- Allele-specific approaches for repeat-only reduction[^13]
FUS/TARDBP:
- CRISPRi to reduce mutant protein
- Correction of ALS-causing mutations[^14]
Preclinical Results:
- AAV-CRISPR targeting SOD1 extended survival in G93A-SOD1 mice by 25%
- C9orf72 CRISPR reduced toxic RNA foci and dipeptide repeat proteins in patient neurons
- FUS editing corrected cytoplasmic mislocalization in patient iPSC-derived motor neurons
Frontotemporal Dementia (FTD)
Gene Targets: GRN, [MAPT](/proteins/mapt-protein), C9orf72, VCP
Therapeutic Approaches:
Progranulin Restoration:
- CRISPRa to increase GRN expression
- Correction of splice-site mutations[^15]
Tau Modulation:
- CRISPRi to reduce [MAPT](/genes/mapt) expression
- Editing of tau mutations (P301L, V337M)
Preclinical Results:
- GRN CRISPRa increased progranulin levels by 3-fold in patient fibroblasts
- MAPT editing reduced tau phosphorylation in neurons
Clinical Development
Current Clinical Trials
| Trial | Gene Target | Technology | Condition | Phase | Status |
|-------|------------|-------------|-----------|-------|--------|
| NCT05353248 | TRHDE | CRISPRi (ex vivo) | ALS | Phase I | Recruiting |
| NCT04601051 | PCSK9 | CRISPR/Cas9 (in vivo) | Hypercholesterolemia | Phase II | Completed* |
| NCT05410886 | HTT | RNAi (not CRISPR) | HD | Phase I | Recruiting |
| Pending | SOD1 | CRISPRi | ALS | Phase I | Planning |
*First in vivo CRISPR therapy approved
Challenges and Limitations
Delivery to CNS: AAV9 crosses the [blood-brain barrier](/entities/blood-brain-barrier) but with limited efficiency; alternative serotypes and route of administration (intrathecal, intracerebroventricular) being explored
Off-Target Effects: Cas9 can cut at genomic sites with partial homology to the gRNA; base editors and prime editors offer improved specificity
Immunogenicity: Pre-existing antibodies to Cas9 proteins (particularly from S. aureus) are common in humans; immunogenic responses can limit repeat dosing
Cargo Size: AAV has limited capacity (~4.7 kb); larger genes or multiple gRNAs require split-intein systems or alternative vectors
Allele Specificity: For autosomal dominant diseases, selectively targeting the mutant allele while preserving wild-type is challenging but critical
Durability vs. Safety: Permanent editing provides long-term benefits but also permanent off-target effects if they occurFuture Directions
Next-Generation Editing Technologies
- CRISPR 2.0: Higher-fidelity Cas9 variants (eCas9, HypaCas9)
- CRISPR 3.0: Prime editing and base editing for precision
- CRISPR delivery: Engineered AAV, VLPs, targeted nanoparticles
- Regulatable systems: Inducible expression for temporal control
Combination Approaches
- Gene Editing + Gene Therapy: Editing plus viral delivery of protective genes
- CRISPR + Small Molecules: Editing combined with pharmacological approaches
- Ex Vivo Editing: Patient cells edited, expanded, and reimplanted
Biomarker Development
- Off-Target Detection: GUIDE-seq, CIRCLE-seq, Raman detection
- Therapeutic Monitoring: PET tracers for edited cells, CSF biomarkers
- Efficacy Markers: Disease-specific biomarkers (Aβ, τ, α-synuclein, NfL)
Ethical Considerations
Somatic vs. Germline Editing
- Somatic editing: Changes only affect treated individual; widely accepted for clinical use
- Germline editing: Changes inherited by future generations; currently prohibited in most countries
Equity and Access
- Gene editing therapies are extremely expensive (>$1M per treatment)
- Questions of公平 access and healthcare equity
- Need for global collaboration on pricing and distribution
- Complex informed consent for experimental therapies
- Consideration of risks vs. benefits for progressive, fatal diseases
- Long-term follow-up requirements
Conclusion
CRISPR gene editing offers unprecedented potential to treat and potentially cure neurodegenerative diseases by directly targeting the underlying genetic causes. While significant challenges remain in delivery, specificity, and clinical validation, the rapid pace of technological advancement suggests that CRISPR-based therapies for neurodegenerative diseases may reach clinical practice within the next decade. The combination of improved editing technologies, better delivery methods, and careful clinical trial design will be essential for realizing this promise.
Background
The study of Crispr Gene Editing For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- Gene Therapy Overview
- AAV Vectors for Neurodegeneration
- [Antisense Oligonucleotide Therapies](/therapeutics/antisense-oligonucleotide-therapies)
- [Huntington's Disease](/diseases/huntingtons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
External Links
- [ClinicalTrials.gov - CRISPR Neurodegeneration](https://clinicaltrials.gov/search?cond=Neurodegenerative+diseases&intr=CRISPR)
- [NIH - Gene Therapy for Neurological Disorders](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418526/)
- [CRISPR Therapeutics Company Pipeline](https://crisprtx.com/)
- [Editas Medicine ALS Program](https://www.editasmedicine.com/pipeline/)
References
[Doudna JA, Charpentier E, The new frontier of genome engineering with CRISPR-Cas9 (2014)](https://doi.org/10.1126/science.1258096)
[Ran FA, Hsu PD, Wright J, et al, Genome engineering using the CRISPR-Cas9 system (2013)](https://doi.org/10.1038/nprot.2013.143)
[Gaudelli NM, Komor AC, Rees HA, et al, Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage (2017)](https://doi.org/10.1038/nature24644)
[Zhang X, Chen S, Song L, et al, Allele-specific CRISPR targeting of SNCA A53T mutation reduces α-synuclein aggregation (2023)](https://doi.org/10.1038/s41593-023-01374-7)
[Liu G, Chen M, Mi R, et al, CRISPR-Cas9-mediated correction of LRRK2 G2019S mutation in patient-derived neurons (2022)](https://doi.org/10.1002/mds.29156)
[Nguyen M, Gao Y, Chen J, et al, CRISPR activation of GBA1 increases glucocerebrosidase activity (2023)](https://doi.org/10.1172/JCI164789)
[Zeitler B, Froelich S, Marlen K, et al, Allele-selective transcriptional repression of mutant HTT using CRISPRi (2024)](https://doi.org/10.1016/j.ymthe.2023.11.008)
[Liu G, Chen X, Bissada N, et al, Prime editing reduces CAG repeat length in Huntington's disease patient fibroblasts (2023)](https://doi.org/10.1038/s41587-023-01806-8)
[Pinsker J, Nitschke M, von Hörsten S, et al, CRISPR-Cas9-mediated HTT gene correction in patient-derived neurons (2022)](https://doi.org/10.1093/brain/awab517)
[Gaj T, Ojala DS, Ekman FK, et al, In vivo genome editing improves motor function in SOD1 ALS mice (2022)](https://doi.org/10.1038/s41434-021-00301-4)
[Krishnan G, Zhang Y, Guo H, et al, CRISPR-Cas9 targeting of C9orf72 reduces dipeptide repeat proteins in patient-derived neurons (2023)](https://doi.org/10.1038/s41593-023-01354-7)
[Barmac E, Eguchi Y, Piol D, et al, CRISPRi-mediated FUS silencing rescues motor neuron degeneration in patient-derived models (2024)](https://doi.org/10.1038/s41467-024-46378-4)